nodes	percent_of_prediction	percent_of_DWPC	metapath
Trifluoperazine—CYP1A2—chronic obstructive pulmonary disease	0.31	0.542	CbGaD
Trifluoperazine—HTR2A—chronic obstructive pulmonary disease	0.261	0.458	CbGaD
Trifluoperazine—CHRM2—Tiotropium—chronic obstructive pulmonary disease	0.0622	0.556	CbGbCtD
Trifluoperazine—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0263	0.235	CbGbCtD
Trifluoperazine—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.012	0.107	CbGbCtD
Trifluoperazine—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.0113	0.101	CbGbCtD
Trifluoperazine—HTR2A—phrenic nerve—chronic obstructive pulmonary disease	0.0103	0.143	CbGeAlD
Trifluoperazine—Brain injury—Aminophylline—chronic obstructive pulmonary disease	0.00968	0.079	CcSEcCtD
Trifluoperazine—EBPL—respiratory system—chronic obstructive pulmonary disease	0.00458	0.0635	CbGeAlD
Trifluoperazine—HTR2A—pulmonary artery—chronic obstructive pulmonary disease	0.00375	0.052	CbGeAlD
Trifluoperazine—S100A4—respiratory system—chronic obstructive pulmonary disease	0.00362	0.0501	CbGeAlD
Trifluoperazine—S100A4—connective tissue—chronic obstructive pulmonary disease	0.00318	0.0441	CbGeAlD
Trifluoperazine—UGT1A4—respiratory system—chronic obstructive pulmonary disease	0.00318	0.044	CbGeAlD
Trifluoperazine—Ileus paralytic—Tiotropium—chronic obstructive pulmonary disease	0.00306	0.025	CcSEcCtD
Trifluoperazine—S100A4—bronchus—chronic obstructive pulmonary disease	0.00298	0.0412	CbGeAlD
Trifluoperazine—S100A4—smooth muscle tissue—chronic obstructive pulmonary disease	0.00291	0.0403	CbGeAlD
Trifluoperazine—TNNC1—connective tissue—chronic obstructive pulmonary disease	0.00268	0.0371	CbGeAlD
Trifluoperazine—S100A4—trachea—chronic obstructive pulmonary disease	0.00267	0.037	CbGeAlD
Trifluoperazine—EBPL—lung—chronic obstructive pulmonary disease	0.00243	0.0337	CbGeAlD
Trifluoperazine—Pigmentation skin—Prednisone—chronic obstructive pulmonary disease	0.0023	0.0188	CcSEcCtD
Trifluoperazine—S100A4—lung—chronic obstructive pulmonary disease	0.00192	0.0266	CbGeAlD
Trifluoperazine—Ventricular arrhythmia—Aminophylline—chronic obstructive pulmonary disease	0.0019	0.0155	CcSEcCtD
Trifluoperazine—Gynaecomastia—Roflumilast—chronic obstructive pulmonary disease	0.00188	0.0154	CcSEcCtD
Trifluoperazine—TNNC1—lung—chronic obstructive pulmonary disease	0.00162	0.0224	CbGeAlD
Trifluoperazine—Ileus—Salbutamol—chronic obstructive pulmonary disease	0.00143	0.0116	CcSEcCtD
Trifluoperazine—S100A4—Desoximetasone—Prednisone—chronic obstructive pulmonary disease	0.00133	0.506	CbGdCrCtD
Trifluoperazine—Glycosuria—Arformoterol—chronic obstructive pulmonary disease	0.00132	0.0108	CcSEcCtD
Trifluoperazine—Glycosuria—Formoterol—chronic obstructive pulmonary disease	0.00132	0.0108	CcSEcCtD
Trifluoperazine—S100A4—Desoximetasone—Prednisolone—chronic obstructive pulmonary disease	0.00129	0.494	CbGdCrCtD
Trifluoperazine—Mydriasis—Salbutamol—chronic obstructive pulmonary disease	0.00126	0.0103	CcSEcCtD
Trifluoperazine—Pigmentation disorder—Prednisone—chronic obstructive pulmonary disease	0.00126	0.0103	CcSEcCtD
Trifluoperazine—Glycosuria—Salbutamol—chronic obstructive pulmonary disease	0.00125	0.0102	CcSEcCtD
Trifluoperazine—Liver injury—Montelukast—chronic obstructive pulmonary disease	0.00124	0.0101	CcSEcCtD
Trifluoperazine—CALM3—bronchus—chronic obstructive pulmonary disease	0.00109	0.0151	CbGeAlD
Trifluoperazine—Dermatitis exfoliative—Aminophylline—chronic obstructive pulmonary disease	0.00108	0.00881	CcSEcCtD
Trifluoperazine—CALM3—smooth muscle tissue—chronic obstructive pulmonary disease	0.00107	0.0148	CbGeAlD
Trifluoperazine—Anaphylactoid reaction—Aminophylline—chronic obstructive pulmonary disease	0.00105	0.00859	CcSEcCtD
Trifluoperazine—Hepatocellular injury—Montelukast—chronic obstructive pulmonary disease	0.00105	0.00854	CcSEcCtD
Trifluoperazine—Menstruation irregular—Prednisolone—chronic obstructive pulmonary disease	0.00105	0.00853	CcSEcCtD
Trifluoperazine—CALM2—respiratory system—chronic obstructive pulmonary disease	0.00104	0.0144	CbGeAlD
Trifluoperazine—CALM1—respiratory system—chronic obstructive pulmonary disease	0.00104	0.0144	CbGeAlD
Trifluoperazine—CALM3—trachea—chronic obstructive pulmonary disease	0.00098	0.0136	CbGeAlD
Trifluoperazine—SIGMAR1—bronchus—chronic obstructive pulmonary disease	0.000975	0.0135	CbGeAlD
Trifluoperazine—Urinary retention—Aminophylline—chronic obstructive pulmonary disease	0.000969	0.00791	CcSEcCtD
Trifluoperazine—DRD2—respiratory system—chronic obstructive pulmonary disease	0.000957	0.0133	CbGeAlD
Trifluoperazine—SIGMAR1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000954	0.0132	CbGeAlD
Trifluoperazine—CALM2—connective tissue—chronic obstructive pulmonary disease	0.000916	0.0127	CbGeAlD
Trifluoperazine—Urinary retention—Tiotropium—chronic obstructive pulmonary disease	0.000914	0.00746	CcSEcCtD
Trifluoperazine—CALM1—connective tissue—chronic obstructive pulmonary disease	0.000912	0.0126	CbGeAlD
Trifluoperazine—Nervousness—Roflumilast—chronic obstructive pulmonary disease	0.000894	0.00729	CcSEcCtD
Trifluoperazine—Muscle spasms—Roflumilast—chronic obstructive pulmonary disease	0.000885	0.00722	CcSEcCtD
Trifluoperazine—SIGMAR1—trachea—chronic obstructive pulmonary disease	0.000876	0.0121	CbGeAlD
Trifluoperazine—Tremor—Roflumilast—chronic obstructive pulmonary disease	0.000862	0.00704	CcSEcCtD
Trifluoperazine—CALM2—bronchus—chronic obstructive pulmonary disease	0.000857	0.0119	CbGeAlD
Trifluoperazine—CALM1—bronchus—chronic obstructive pulmonary disease	0.000853	0.0118	CbGeAlD
Trifluoperazine—Nasal congestion—Formoterol—chronic obstructive pulmonary disease	0.000851	0.00695	CcSEcCtD
Trifluoperazine—Nasal congestion—Arformoterol—chronic obstructive pulmonary disease	0.000851	0.00695	CcSEcCtD
Trifluoperazine—Eczema—Montelukast—chronic obstructive pulmonary disease	0.000845	0.0069	CcSEcCtD
Trifluoperazine—Angioedema—Roflumilast—chronic obstructive pulmonary disease	0.000841	0.00686	CcSEcCtD
Trifluoperazine—CALM2—smooth muscle tissue—chronic obstructive pulmonary disease	0.000838	0.0116	CbGeAlD
Trifluoperazine—CALM1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000834	0.0116	CbGeAlD
Trifluoperazine—Dysphagia—Tiotropium—chronic obstructive pulmonary disease	0.000831	0.00678	CcSEcCtD
Trifluoperazine—Eczema—Salbutamol—chronic obstructive pulmonary disease	0.000815	0.00665	CcSEcCtD
Trifluoperazine—CYP1A2—respiratory system—chronic obstructive pulmonary disease	0.000807	0.0112	CbGeAlD
Trifluoperazine—Nasal congestion—Salbutamol—chronic obstructive pulmonary disease	0.000804	0.00656	CcSEcCtD
Trifluoperazine—Hypoglycaemia—Formoterol—chronic obstructive pulmonary disease	0.000795	0.00649	CcSEcCtD
Trifluoperazine—Hypoglycaemia—Arformoterol—chronic obstructive pulmonary disease	0.000795	0.00649	CcSEcCtD
Trifluoperazine—Hyperglycaemia—Aminophylline—chronic obstructive pulmonary disease	0.000794	0.00648	CcSEcCtD
Trifluoperazine—Increased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000779	0.00636	CcSEcCtD
Trifluoperazine—CALM2—trachea—chronic obstructive pulmonary disease	0.000769	0.0107	CbGeAlD
Trifluoperazine—CALM1—trachea—chronic obstructive pulmonary disease	0.000766	0.0106	CbGeAlD
Trifluoperazine—Menstruation irregular—Prednisone—chronic obstructive pulmonary disease	0.000759	0.0062	CcSEcCtD
Trifluoperazine—HRH1—respiratory system—chronic obstructive pulmonary disease	0.000756	0.0105	CbGeAlD
Trifluoperazine—Hypoglycaemia—Salbutamol—chronic obstructive pulmonary disease	0.00075	0.00612	CcSEcCtD
Trifluoperazine—Hyperglycaemia—Tiotropium—chronic obstructive pulmonary disease	0.000749	0.00611	CcSEcCtD
Trifluoperazine—Skin disorder—Roflumilast—chronic obstructive pulmonary disease	0.00073	0.00595	CcSEcCtD
Trifluoperazine—Mydriasis—Prednisolone—chronic obstructive pulmonary disease	0.000725	0.00592	CcSEcCtD
Trifluoperazine—CALM3—lung—chronic obstructive pulmonary disease	0.000704	0.00975	CbGeAlD
Trifluoperazine—Insomnia—Roflumilast—chronic obstructive pulmonary disease	0.000679	0.00554	CcSEcCtD
Trifluoperazine—Asthma—Arformoterol—chronic obstructive pulmonary disease	0.00067	0.00547	CcSEcCtD
Trifluoperazine—Asthma—Formoterol—chronic obstructive pulmonary disease	0.00067	0.00547	CcSEcCtD
Trifluoperazine—HRH1—connective tissue—chronic obstructive pulmonary disease	0.000665	0.00922	CbGeAlD
Trifluoperazine—Bronchospasm—Formoterol—chronic obstructive pulmonary disease	0.000659	0.00538	CcSEcCtD
Trifluoperazine—Bronchospasm—Arformoterol—chronic obstructive pulmonary disease	0.000659	0.00538	CcSEcCtD
Trifluoperazine—Asthma—Montelukast—chronic obstructive pulmonary disease	0.000657	0.00536	CcSEcCtD
Trifluoperazine—Oedema peripheral—Tiotropium—chronic obstructive pulmonary disease	0.000655	0.00534	CcSEcCtD
Trifluoperazine—Decreased appetite—Roflumilast—chronic obstructive pulmonary disease	0.000653	0.00533	CcSEcCtD
Trifluoperazine—Eosinophilia—Montelukast—chronic obstructive pulmonary disease	0.00065	0.00531	CcSEcCtD
Trifluoperazine—Fatigue—Roflumilast—chronic obstructive pulmonary disease	0.000648	0.00528	CcSEcCtD
Trifluoperazine—Constipation—Roflumilast—chronic obstructive pulmonary disease	0.000642	0.00524	CcSEcCtD
Trifluoperazine—Asthma—Salbutamol—chronic obstructive pulmonary disease	0.000633	0.00517	CcSEcCtD
Trifluoperazine—HTR2A—respiratory system—chronic obstructive pulmonary disease	0.000631	0.00875	CbGeAlD
Trifluoperazine—SIGMAR1—lung—chronic obstructive pulmonary disease	0.000629	0.00872	CbGeAlD
Trifluoperazine—Bronchospasm—Salbutamol—chronic obstructive pulmonary disease	0.000623	0.00508	CcSEcCtD
Trifluoperazine—HRH1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000609	0.00843	CbGeAlD
Trifluoperazine—Hyperglycaemia—Arformoterol—chronic obstructive pulmonary disease	0.000605	0.00493	CcSEcCtD
Trifluoperazine—Hyperglycaemia—Formoterol—chronic obstructive pulmonary disease	0.000605	0.00493	CcSEcCtD
Trifluoperazine—Urticaria—Roflumilast—chronic obstructive pulmonary disease	0.000597	0.00487	CcSEcCtD
Trifluoperazine—Nervousness—Aminophylline—chronic obstructive pulmonary disease	0.000596	0.00486	CcSEcCtD
Trifluoperazine—Drowsiness—Montelukast—chronic obstructive pulmonary disease	0.000585	0.00478	CcSEcCtD
Trifluoperazine—Tremor—Aminophylline—chronic obstructive pulmonary disease	0.000575	0.00469	CcSEcCtD
Trifluoperazine—Hyperglycaemia—Salbutamol—chronic obstructive pulmonary disease	0.000571	0.00466	CcSEcCtD
Trifluoperazine—Jaundice—Montelukast—chronic obstructive pulmonary disease	0.000571	0.00466	CcSEcCtD
Trifluoperazine—Drowsiness—Salbutamol—chronic obstructive pulmonary disease	0.000564	0.00461	CcSEcCtD
Trifluoperazine—Agitation—Aminophylline—chronic obstructive pulmonary disease	0.000564	0.0046	CcSEcCtD
Trifluoperazine—HRH1—trachea—chronic obstructive pulmonary disease	0.000559	0.00774	CbGeAlD
Trifluoperazine—HTR2A—connective tissue—chronic obstructive pulmonary disease	0.000556	0.0077	CbGeAlD
Trifluoperazine—Hypersensitivity—Roflumilast—chronic obstructive pulmonary disease	0.000553	0.00452	CcSEcCtD
Trifluoperazine—CALM2—lung—chronic obstructive pulmonary disease	0.000553	0.00766	CbGeAlD
Trifluoperazine—CALM1—lung—chronic obstructive pulmonary disease	0.00055	0.00762	CbGeAlD
Trifluoperazine—Jaundice—Salbutamol—chronic obstructive pulmonary disease	0.00055	0.00449	CcSEcCtD
Trifluoperazine—Vision blurred—Tiotropium—chronic obstructive pulmonary disease	0.000545	0.00445	CcSEcCtD
Trifluoperazine—Asthenia—Roflumilast—chronic obstructive pulmonary disease	0.000539	0.0044	CcSEcCtD
Trifluoperazine—Convulsion—Aminophylline—chronic obstructive pulmonary disease	0.000532	0.00434	CcSEcCtD
Trifluoperazine—Angioedema—Tiotropium—chronic obstructive pulmonary disease	0.000529	0.00432	CcSEcCtD
Trifluoperazine—Oedema peripheral—Arformoterol—chronic obstructive pulmonary disease	0.000529	0.00431	CcSEcCtD
Trifluoperazine—Oedema peripheral—Formoterol—chronic obstructive pulmonary disease	0.000529	0.00431	CcSEcCtD
Trifluoperazine—Glycosuria—Prednisone—chronic obstructive pulmonary disease	0.000519	0.00424	CcSEcCtD
Trifluoperazine—HTR2A—smooth muscle tissue—chronic obstructive pulmonary disease	0.000508	0.00704	CbGeAlD
Trifluoperazine—DRD2—lung—chronic obstructive pulmonary disease	0.000508	0.00704	CbGeAlD
Trifluoperazine—Cough—Tiotropium—chronic obstructive pulmonary disease	0.000505	0.00412	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Aminophylline—chronic obstructive pulmonary disease	0.000501	0.00409	CcSEcCtD
Trifluoperazine—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.000497	0.00405	CcSEcCtD
Trifluoperazine—Dry mouth—Tiotropium—chronic obstructive pulmonary disease	0.000482	0.00393	CcSEcCtD
Trifluoperazine—Amenorrhoea—Prednisone—chronic obstructive pulmonary disease	0.000479	0.00391	CcSEcCtD
Trifluoperazine—Anorexia—Aminophylline—chronic obstructive pulmonary disease	0.000477	0.0039	CcSEcCtD
Trifluoperazine—Rash—Roflumilast—chronic obstructive pulmonary disease	0.000474	0.00386	CcSEcCtD
Trifluoperazine—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.000473	0.00386	CcSEcCtD
Trifluoperazine—Headache—Roflumilast—chronic obstructive pulmonary disease	0.00047	0.00384	CcSEcCtD
Trifluoperazine—Hypotension—Aminophylline—chronic obstructive pulmonary disease	0.000468	0.00382	CcSEcCtD
Trifluoperazine—HTR2A—trachea—chronic obstructive pulmonary disease	0.000466	0.00646	CbGeAlD
Trifluoperazine—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.000459	0.00374	CcSEcCtD
Trifluoperazine—Nervousness—Formoterol—chronic obstructive pulmonary disease	0.000454	0.0037	CcSEcCtD
Trifluoperazine—Nervousness—Arformoterol—chronic obstructive pulmonary disease	0.000454	0.0037	CcSEcCtD
Trifluoperazine—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.000453	0.0037	CcSEcCtD
Trifluoperazine—Muscle spasms—Formoterol—chronic obstructive pulmonary disease	0.000449	0.00366	CcSEcCtD
Trifluoperazine—Muscle spasms—Arformoterol—chronic obstructive pulmonary disease	0.000449	0.00366	CcSEcCtD
Trifluoperazine—Increased appetite—Prednisolone—chronic obstructive pulmonary disease	0.000447	0.00365	CcSEcCtD
Trifluoperazine—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000446	0.00364	CcSEcCtD
Trifluoperazine—Muscle spasms—Montelukast—chronic obstructive pulmonary disease	0.00044	0.00359	CcSEcCtD
Trifluoperazine—Tremor—Formoterol—chronic obstructive pulmonary disease	0.000438	0.00357	CcSEcCtD
Trifluoperazine—Tremor—Arformoterol—chronic obstructive pulmonary disease	0.000438	0.00357	CcSEcCtD
Trifluoperazine—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.000435	0.00355	CcSEcCtD
Trifluoperazine—Anaphylactoid reaction—Prednisolone—chronic obstructive pulmonary disease	0.000434	0.00354	CcSEcCtD
Trifluoperazine—Agitation—Arformoterol—chronic obstructive pulmonary disease	0.000429	0.0035	CcSEcCtD
Trifluoperazine—Agitation—Formoterol—chronic obstructive pulmonary disease	0.000429	0.0035	CcSEcCtD
Trifluoperazine—CYP1A2—lung—chronic obstructive pulmonary disease	0.000429	0.00594	CbGeAlD
Trifluoperazine—Tremor—Montelukast—chronic obstructive pulmonary disease	0.000429	0.0035	CcSEcCtD
Trifluoperazine—Nervousness—Salbutamol—chronic obstructive pulmonary disease	0.000428	0.0035	CcSEcCtD
Trifluoperazine—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.000427	0.00349	CcSEcCtD
Trifluoperazine—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.000427	0.00348	CcSEcCtD
Trifluoperazine—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.000427	0.00348	CcSEcCtD
Trifluoperazine—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	0.000424	0.00346	CcSEcCtD
Trifluoperazine—Agitation—Montelukast—chronic obstructive pulmonary disease	0.00042	0.00343	CcSEcCtD
Trifluoperazine—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.000418	0.00341	CcSEcCtD
Trifluoperazine—ABCB1—respiratory system—chronic obstructive pulmonary disease	0.000414	0.00573	CbGeAlD
Trifluoperazine—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000413	0.00337	CcSEcCtD
Trifluoperazine—Cough—Arformoterol—chronic obstructive pulmonary disease	0.000408	0.00333	CcSEcCtD
Trifluoperazine—Cough—Formoterol—chronic obstructive pulmonary disease	0.000408	0.00333	CcSEcCtD
Trifluoperazine—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.000405	0.00331	CcSEcCtD
Trifluoperazine—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000404	0.0033	CcSEcCtD
Trifluoperazine—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.000403	0.00329	CcSEcCtD
Trifluoperazine—HRH1—lung—chronic obstructive pulmonary disease	0.000401	0.00556	CbGeAlD
Trifluoperazine—Cardiac arrest—Prednisolone—chronic obstructive pulmonary disease	0.000399	0.00326	CcSEcCtD
Trifluoperazine—Cough—Montelukast—chronic obstructive pulmonary disease	0.000399	0.00326	CcSEcCtD
Trifluoperazine—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000398	0.00325	CcSEcCtD
Trifluoperazine—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.000396	0.00323	CcSEcCtD
Trifluoperazine—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000396	0.00323	CcSEcCtD
Trifluoperazine—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000389	0.00317	CcSEcCtD
Trifluoperazine—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000389	0.00317	CcSEcCtD
Trifluoperazine—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000385	0.00314	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000381	0.00311	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000381	0.00311	CcSEcCtD
Trifluoperazine—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000375	0.00306	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000373	0.00305	CcSEcCtD
Trifluoperazine—Muscular weakness—Prednisolone—chronic obstructive pulmonary disease	0.00037	0.00302	CcSEcCtD
Trifluoperazine—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.00037	0.00302	CcSEcCtD
Trifluoperazine—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.00037	0.00302	CcSEcCtD
Trifluoperazine—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000369	0.00301	CcSEcCtD
Trifluoperazine—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000367	0.003	CcSEcCtD
Trifluoperazine—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000363	0.00296	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.00036	0.00294	CcSEcCtD
Trifluoperazine—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000356	0.00291	CcSEcCtD
Trifluoperazine—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000356	0.00291	CcSEcCtD
Trifluoperazine—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000354	0.00289	CcSEcCtD
Trifluoperazine—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.00035	0.00285	CcSEcCtD
Trifluoperazine—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000348	0.00284	CcSEcCtD
Trifluoperazine—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000345	0.00281	CcSEcCtD
Trifluoperazine—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000345	0.00281	CcSEcCtD
Trifluoperazine—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000343	0.0028	CcSEcCtD
Trifluoperazine—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.00034	0.00277	CcSEcCtD
Trifluoperazine—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.00034	0.00277	CcSEcCtD
Trifluoperazine—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000339	0.00277	CcSEcCtD
Trifluoperazine—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000339	0.00277	CcSEcCtD
Trifluoperazine—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000338	0.00276	CcSEcCtD
Trifluoperazine—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000336	0.00274	CcSEcCtD
Trifluoperazine—HTR2A—lung—chronic obstructive pulmonary disease	0.000335	0.00464	CbGeAlD
Trifluoperazine—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000334	0.00273	CcSEcCtD
Trifluoperazine—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000332	0.00271	CcSEcCtD
Trifluoperazine—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000331	0.0027	CcSEcCtD
Trifluoperazine—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.00033	0.0027	CcSEcCtD
Trifluoperazine—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000329	0.00268	CcSEcCtD
Trifluoperazine—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000329	0.00268	CcSEcCtD
Trifluoperazine—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000326	0.00266	CcSEcCtD
Trifluoperazine—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000326	0.00266	CcSEcCtD
Trifluoperazine—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000326	0.00266	CcSEcCtD
Trifluoperazine—Increased appetite—Prednisone—chronic obstructive pulmonary disease	0.000325	0.00265	CcSEcCtD
Trifluoperazine—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000322	0.00263	CcSEcCtD
Trifluoperazine—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000321	0.00262	CcSEcCtD
Trifluoperazine—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.00032	0.00261	CcSEcCtD
Trifluoperazine—Flupentixol—HTR2A—chronic obstructive pulmonary disease	0.000317	0.0509	CrCbGaD
Trifluoperazine—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000316	0.00258	CcSEcCtD
Trifluoperazine—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000315	0.00257	CcSEcCtD
Trifluoperazine—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000314	0.00256	CcSEcCtD
Trifluoperazine—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000313	0.00255	CcSEcCtD
Trifluoperazine—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000312	0.00255	CcSEcCtD
Trifluoperazine—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.00031	0.00253	CcSEcCtD
Trifluoperazine—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000308	0.00251	CcSEcCtD
Trifluoperazine—ABCB1—trachea—chronic obstructive pulmonary disease	0.000306	0.00424	CbGeAlD
Trifluoperazine—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000303	0.00247	CcSEcCtD
Trifluoperazine—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000303	0.00247	CcSEcCtD
Trifluoperazine—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000301	0.00246	CcSEcCtD
Trifluoperazine—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000301	0.00246	CcSEcCtD
Trifluoperazine—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000298	0.00243	CcSEcCtD
Trifluoperazine—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000298	0.00243	CcSEcCtD
Trifluoperazine—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000297	0.00243	CcSEcCtD
Trifluoperazine—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000297	0.00242	CcSEcCtD
Trifluoperazine—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000296	0.00241	CcSEcCtD
Trifluoperazine—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000295	0.00241	CcSEcCtD
Trifluoperazine—Clomipramine—GSTP1—chronic obstructive pulmonary disease	0.000295	0.0473	CrCbGaD
Trifluoperazine—Cardiac arrest—Prednisone—chronic obstructive pulmonary disease	0.00029	0.00237	CcSEcCtD
Trifluoperazine—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000286	0.00233	CcSEcCtD
Trifluoperazine—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000285	0.00232	CcSEcCtD
Trifluoperazine—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000281	0.00229	CcSEcCtD
Trifluoperazine—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000281	0.00229	CcSEcCtD
Trifluoperazine—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000281	0.00229	CcSEcCtD
Trifluoperazine—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000275	0.00224	CcSEcCtD
Trifluoperazine—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000273	0.00223	CcSEcCtD
Trifluoperazine—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000273	0.00223	CcSEcCtD
Trifluoperazine—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.00027	0.0022	CcSEcCtD
Trifluoperazine—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.00027	0.0022	CcSEcCtD
Trifluoperazine—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	0.000269	0.0022	CcSEcCtD
Trifluoperazine—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000268	0.00219	CcSEcCtD
Trifluoperazine—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000265	0.00216	CcSEcCtD
Trifluoperazine—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000264	0.00216	CcSEcCtD
Trifluoperazine—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000258	0.00211	CcSEcCtD
Trifluoperazine—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000255	0.00208	CcSEcCtD
Trifluoperazine—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.000253	0.00206	CcSEcCtD
Trifluoperazine—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000252	0.00206	CcSEcCtD
Trifluoperazine—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000252	0.00206	CcSEcCtD
Trifluoperazine—Cyamemazine—HTR2A—chronic obstructive pulmonary disease	0.000249	0.0399	CrCbGaD
Trifluoperazine—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000247	0.00201	CcSEcCtD
Trifluoperazine—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.000243	0.00198	CcSEcCtD
Trifluoperazine—Rash—Arformoterol—chronic obstructive pulmonary disease	0.00024	0.00196	CcSEcCtD
Trifluoperazine—Rash—Formoterol—chronic obstructive pulmonary disease	0.00024	0.00196	CcSEcCtD
Trifluoperazine—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.00024	0.00196	CcSEcCtD
Trifluoperazine—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.00024	0.00196	CcSEcCtD
Trifluoperazine—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.00024	0.00196	CcSEcCtD
Trifluoperazine—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000239	0.00195	CcSEcCtD
Trifluoperazine—Headache—Formoterol—chronic obstructive pulmonary disease	0.000239	0.00195	CcSEcCtD
Trifluoperazine—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000238	0.00195	CcSEcCtD
Trifluoperazine—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000238	0.00194	CcSEcCtD
Trifluoperazine—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000238	0.00194	CcSEcCtD
Trifluoperazine—Rash—Montelukast—chronic obstructive pulmonary disease	0.000235	0.00192	CcSEcCtD
Trifluoperazine—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000235	0.00192	CcSEcCtD
Trifluoperazine—Headache—Montelukast—chronic obstructive pulmonary disease	0.000234	0.00191	CcSEcCtD
Trifluoperazine—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000231	0.00189	CcSEcCtD
Trifluoperazine—Nefazodone—SLC6A4—chronic obstructive pulmonary disease	0.000231	0.037	CrCbGaD
Trifluoperazine—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000227	0.00185	CcSEcCtD
Trifluoperazine—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000227	0.00185	CcSEcCtD
Trifluoperazine—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000226	0.00185	CcSEcCtD
Trifluoperazine—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000226	0.00185	CcSEcCtD
Trifluoperazine—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000225	0.00184	CcSEcCtD
Trifluoperazine—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000222	0.00181	CcSEcCtD
Trifluoperazine—ABCB1—lung—chronic obstructive pulmonary disease	0.00022	0.00304	CbGeAlD
Trifluoperazine—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000219	0.00179	CcSEcCtD
Trifluoperazine—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000214	0.00174	CcSEcCtD
Trifluoperazine—Trazodone—SLC6A4—chronic obstructive pulmonary disease	0.000213	0.0342	CrCbGaD
Trifluoperazine—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000206	0.00168	CcSEcCtD
Trifluoperazine—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000187	0.00152	CcSEcCtD
Trifluoperazine—Erythema—Prednisone—chronic obstructive pulmonary disease	0.000184	0.0015	CcSEcCtD
Trifluoperazine—Thiothixene—CYP1A2—chronic obstructive pulmonary disease	0.000182	0.0292	CrCbGaD
Trifluoperazine—Pipotiazine—CYP1A2—chronic obstructive pulmonary disease	0.000182	0.0292	CrCbGaD
Trifluoperazine—Zuclopenthixol—HTR2A—chronic obstructive pulmonary disease	0.000178	0.0286	CrCbGaD
Trifluoperazine—Nefazodone—HTR2A—chronic obstructive pulmonary disease	0.000177	0.0284	CrCbGaD
Trifluoperazine—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000173	0.00141	CcSEcCtD
Trifluoperazine—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000169	0.00138	CcSEcCtD
Trifluoperazine—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000168	0.00137	CcSEcCtD
Trifluoperazine—Trazodone—HTR2A—chronic obstructive pulmonary disease	0.000164	0.0263	CrCbGaD
Trifluoperazine—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000164	0.00134	CcSEcCtD
Trifluoperazine—Acepromazine—HTR2A—chronic obstructive pulmonary disease	0.00016	0.0256	CrCbGaD
Trifluoperazine—Convulsion—Prednisone—chronic obstructive pulmonary disease	0.000159	0.0013	CcSEcCtD
Trifluoperazine—Clomipramine—SLC6A4—chronic obstructive pulmonary disease	0.000158	0.0254	CrCbGaD
Trifluoperazine—Fluphenazine—CYP1A2—chronic obstructive pulmonary disease	0.000157	0.0252	CrCbGaD
Trifluoperazine—Thioproperazine—HTR2A—chronic obstructive pulmonary disease	0.000156	0.0251	CrCbGaD
Trifluoperazine—Thiothixene—HTR2A—chronic obstructive pulmonary disease	0.000154	0.0246	CrCbGaD
Trifluoperazine—Pipotiazine—HTR2A—chronic obstructive pulmonary disease	0.000154	0.0246	CrCbGaD
Trifluoperazine—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000152	0.00124	CcSEcCtD
Trifluoperazine—Mesoridazine—HTR2A—chronic obstructive pulmonary disease	0.000152	0.0243	CrCbGaD
Trifluoperazine—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.00015	0.00122	CcSEcCtD
Trifluoperazine—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000146	0.00119	CcSEcCtD
Trifluoperazine—Clomipramine—CYP1A2—chronic obstructive pulmonary disease	0.000144	0.0231	CrCbGaD
Trifluoperazine—Anorexia—Prednisone—chronic obstructive pulmonary disease	0.000143	0.00117	CcSEcCtD
Trifluoperazine—Loxapine—SLC6A4—chronic obstructive pulmonary disease	0.000137	0.022	CrCbGaD
Trifluoperazine—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000137	0.00111	CcSEcCtD
Trifluoperazine—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000136	0.00111	CcSEcCtD
Trifluoperazine—Thioridazine—CYP1A2—chronic obstructive pulmonary disease	0.000136	0.0217	CrCbGaD
Trifluoperazine—Fluphenazine—HTR2A—chronic obstructive pulmonary disease	0.000133	0.0213	CrCbGaD
Trifluoperazine—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.00013	0.00106	CcSEcCtD
Trifluoperazine—Rash—Prednisolone—chronic obstructive pulmonary disease	0.00013	0.00106	CcSEcCtD
Trifluoperazine—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.00013	0.00106	CcSEcCtD
Trifluoperazine—Methotrimeprazine—CYP1A2—chronic obstructive pulmonary disease	0.000129	0.0208	CrCbGaD
Trifluoperazine—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000129	0.00106	CcSEcCtD
Trifluoperazine—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000129	0.00106	CcSEcCtD
Trifluoperazine—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000128	0.00105	CcSEcCtD
Trifluoperazine—Propiomazine—HTR2A—chronic obstructive pulmonary disease	0.000128	0.0205	CrCbGaD
Trifluoperazine—Perphenazine—CYP1A2—chronic obstructive pulmonary disease	0.000124	0.02	CrCbGaD
Trifluoperazine—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000123	0.001	CcSEcCtD
Trifluoperazine—Clomipramine—HTR2A—chronic obstructive pulmonary disease	0.000121	0.0195	CrCbGaD
Trifluoperazine—Urticaria—Prednisone—chronic obstructive pulmonary disease	0.000119	0.000973	CcSEcCtD
Trifluoperazine—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.000119	0.000968	CcSEcCtD
Trifluoperazine—Thioridazine—HTR2A—chronic obstructive pulmonary disease	0.000114	0.0184	CrCbGaD
Trifluoperazine—Promazine—CYP1A2—chronic obstructive pulmonary disease	0.000112	0.018	CrCbGaD
Trifluoperazine—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000111	0.000902	CcSEcCtD
Trifluoperazine—Acepromazine—ALB—chronic obstructive pulmonary disease	0.000109	0.0175	CrCbGaD
Trifluoperazine—Methotrimeprazine—HTR2A—chronic obstructive pulmonary disease	0.000109	0.0175	CrCbGaD
Trifluoperazine—Clozapine—CYP1A1—chronic obstructive pulmonary disease	0.000109	0.0175	CrCbGaD
Trifluoperazine—Promethazine—HTR2A—chronic obstructive pulmonary disease	0.000108	0.0173	CrCbGaD
Trifluoperazine—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000108	0.000878	CcSEcCtD
Trifluoperazine—Thioproperazine—ALB—chronic obstructive pulmonary disease	0.000107	0.0171	CrCbGaD
Trifluoperazine—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000106	0.000866	CcSEcCtD
Trifluoperazine—Loxapine—HTR2A—chronic obstructive pulmonary disease	0.000106	0.0169	CrCbGaD
Trifluoperazine—Pipotiazine—ALB—chronic obstructive pulmonary disease	0.000105	0.0169	CrCbGaD
Trifluoperazine—Thiothixene—ALB—chronic obstructive pulmonary disease	0.000105	0.0169	CrCbGaD
Trifluoperazine—Perphenazine—HTR2A—chronic obstructive pulmonary disease	0.000105	0.0168	CrCbGaD
Trifluoperazine—Clozapine—CYP1A2—chronic obstructive pulmonary disease	0.000105	0.0168	CrCbGaD
Trifluoperazine—Quetiapine—HTR2A—chronic obstructive pulmonary disease	0.000103	0.0165	CrCbGaD
Trifluoperazine—Dizziness—Prednisone—chronic obstructive pulmonary disease	9.92e-05	0.00081	CcSEcCtD
Trifluoperazine—Chlorpromazine—CYP1A2—chronic obstructive pulmonary disease	9.87e-05	0.0158	CrCbGaD
Trifluoperazine—Promazine—HTR2A—chronic obstructive pulmonary disease	9.47e-05	0.0152	CrCbGaD
Trifluoperazine—Rash—Prednisone—chronic obstructive pulmonary disease	9.46e-05	0.000772	CcSEcCtD
Trifluoperazine—Dermatitis—Prednisone—chronic obstructive pulmonary disease	9.45e-05	0.000771	CcSEcCtD
Trifluoperazine—Headache—Prednisone—chronic obstructive pulmonary disease	9.4e-05	0.000767	CcSEcCtD
Trifluoperazine—Nausea—Prednisone—chronic obstructive pulmonary disease	8.91e-05	0.000727	CcSEcCtD
Trifluoperazine—Clozapine—HTR2A—chronic obstructive pulmonary disease	8.86e-05	0.0142	CrCbGaD
Trifluoperazine—Chlorpromazine—HTR2A—chronic obstructive pulmonary disease	8.33e-05	0.0134	CrCbGaD
Trifluoperazine—Clomipramine—ALB—chronic obstructive pulmonary disease	8.31e-05	0.0133	CrCbGaD
Trifluoperazine—Chlorpromazine—ALB—chronic obstructive pulmonary disease	5.7e-05	0.00914	CrCbGaD
Trifluoperazine—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.03e-05	9.1e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—TLR4—chronic obstructive pulmonary disease	1.03e-05	9.09e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.03e-05	9.06e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.03e-05	9.06e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.03e-05	9.04e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.02e-05	9e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.02e-05	8.96e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.02e-05	8.96e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.02e-05	8.95e-05	CbGpPWpGaD
Trifluoperazine—HRH1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.02e-05	8.94e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.01e-05	8.89e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.01e-05	8.87e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.01e-05	8.87e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—TLR4—chronic obstructive pulmonary disease	1e-05	8.8e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—TLR4—chronic obstructive pulmonary disease	1e-05	8.8e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1e-05	8.79e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Hemostasis—TGFB1—chronic obstructive pulmonary disease	9.98e-06	8.77e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	9.98e-06	8.77e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	9.93e-06	8.73e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—GSTM1—chronic obstructive pulmonary disease	9.92e-06	8.72e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	9.9e-06	8.71e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—KL—chronic obstructive pulmonary disease	9.85e-06	8.66e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—KL—chronic obstructive pulmonary disease	9.85e-06	8.66e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	9.81e-06	8.63e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Hemostasis—TGFB1—chronic obstructive pulmonary disease	9.65e-06	8.48e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Hemostasis—TGFB1—chronic obstructive pulmonary disease	9.65e-06	8.48e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	9.63e-06	8.47e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—GSTM1—chronic obstructive pulmonary disease	9.6e-06	8.44e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—GSTM1—chronic obstructive pulmonary disease	9.6e-06	8.44e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	9.52e-06	8.37e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—LEP—chronic obstructive pulmonary disease	9.47e-06	8.33e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	9.43e-06	8.29e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—CYP1A1—chronic obstructive pulmonary disease	9.41e-06	8.27e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	9.4e-06	8.27e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	9.39e-06	8.26e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	9.34e-06	8.21e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	9.32e-06	8.19e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	9.25e-06	8.13e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	9.23e-06	8.12e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	9.19e-06	8.08e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	9.17e-06	8.06e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	9.1e-06	8e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	9.1e-06	8e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	9.09e-06	7.99e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	9.09e-06	7.99e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—NOS2—chronic obstructive pulmonary disease	9.08e-06	7.99e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	9.08e-06	7.99e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	9.06e-06	7.96e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	9.02e-06	7.93e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	9e-06	7.91e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	8.99e-06	7.9e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	8.83e-06	7.76e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Innate Immune System—EGFR—chronic obstructive pulmonary disease	8.81e-06	7.74e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—NOS2—chronic obstructive pulmonary disease	8.79e-06	7.73e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—NOS2—chronic obstructive pulmonary disease	8.79e-06	7.73e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	8.69e-06	7.64e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	8.69e-06	7.64e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	8.66e-06	7.62e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	8.55e-06	7.51e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Innate Immune System—EGFR—chronic obstructive pulmonary disease	8.52e-06	7.49e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Innate Immune System—EGFR—chronic obstructive pulmonary disease	8.52e-06	7.49e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	8.5e-06	7.47e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Adaptive Immune System—EGFR—chronic obstructive pulmonary disease	8.46e-06	7.43e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	8.39e-06	7.38e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	8.36e-06	7.35e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	8.22e-06	7.23e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Hemostasis—TP53—chronic obstructive pulmonary disease	8.21e-06	7.22e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	8.21e-06	7.21e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.18e-06	7.2e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Adaptive Immune System—EGFR—chronic obstructive pulmonary disease	8.18e-06	7.19e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Adaptive Immune System—EGFR—chronic obstructive pulmonary disease	8.18e-06	7.19e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	8.13e-06	7.14e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	8.12e-06	7.14e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	8.12e-06	7.14e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	8.07e-06	7.1e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.07e-06	7.1e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	8.05e-06	7.08e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Hemostasis—TP53—chronic obstructive pulmonary disease	7.94e-06	6.98e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Hemostasis—TP53—chronic obstructive pulmonary disease	7.94e-06	6.98e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	7.83e-06	6.88e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	7.79e-06	6.85e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	7.73e-06	6.8e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	7.68e-06	6.75e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—SERPINE1—chronic obstructive pulmonary disease	7.65e-06	6.73e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	7.63e-06	6.71e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.52e-06	6.61e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	7.47e-06	6.57e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	7.43e-06	6.53e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	7.43e-06	6.53e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	7.43e-06	6.53e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—SERPINE1—chronic obstructive pulmonary disease	7.4e-06	6.51e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—SERPINE1—chronic obstructive pulmonary disease	7.4e-06	6.51e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	7.38e-06	6.49e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	7.38e-06	6.49e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	7.34e-06	6.46e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—NOS3—chronic obstructive pulmonary disease	7.3e-06	6.42e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.13e-06	6.27e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.13e-06	6.27e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	7.1e-06	6.25e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	7.1e-06	6.25e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.1e-06	6.24e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—NOS3—chronic obstructive pulmonary disease	7.07e-06	6.21e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—NOS3—chronic obstructive pulmonary disease	7.07e-06	6.21e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.94e-06	6.1e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	6.87e-06	6.04e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—LEP—chronic obstructive pulmonary disease	6.83e-06	6e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Innate Immune System—IL6—chronic obstructive pulmonary disease	6.77e-06	5.95e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	6.76e-06	5.95e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	6.75e-06	5.93e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—IL1B—chronic obstructive pulmonary disease	6.73e-06	5.92e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	6.64e-06	5.84e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	6.62e-06	5.82e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	6.6e-06	5.81e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	6.6e-06	5.81e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.56e-06	5.77e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Innate Immune System—IL6—chronic obstructive pulmonary disease	6.55e-06	5.76e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Innate Immune System—IL6—chronic obstructive pulmonary disease	6.55e-06	5.76e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.53e-06	5.74e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—IL1B—chronic obstructive pulmonary disease	6.51e-06	5.72e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—IL1B—chronic obstructive pulmonary disease	6.51e-06	5.72e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.45e-06	5.67e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.44e-06	5.66e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.44e-06	5.66e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—ALB—chronic obstructive pulmonary disease	6.39e-06	5.62e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	6.37e-06	5.6e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.34e-06	5.57e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.33e-06	5.56e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.32e-06	5.56e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.29e-06	5.53e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.26e-06	5.51e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.25e-06	5.49e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—ALB—chronic obstructive pulmonary disease	6.19e-06	5.44e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—ALB—chronic obstructive pulmonary disease	6.19e-06	5.44e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.16e-06	5.42e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.15e-06	5.41e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—NOS3—chronic obstructive pulmonary disease	6.12e-06	5.38e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.05e-06	5.32e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.03e-06	5.3e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	6.02e-06	5.29e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	6e-06	5.28e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	5.98e-06	5.26e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—NOS3—chronic obstructive pulmonary disease	5.92e-06	5.2e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—NOS3—chronic obstructive pulmonary disease	5.92e-06	5.2e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.72e-06	5.03e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.69e-06	5e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.69e-06	5e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	5.61e-06	4.94e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.55e-06	4.88e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.47e-06	4.8e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.45e-06	4.79e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	5.43e-06	4.77e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	5.43e-06	4.77e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.37e-06	4.72e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	5.36e-06	4.71e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.35e-06	4.7e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	5.28e-06	4.64e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.24e-06	4.61e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	5.2e-06	4.57e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	5.19e-06	4.56e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	5.18e-06	4.56e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	5.18e-06	4.56e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.14e-06	4.52e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—EGFR—chronic obstructive pulmonary disease	5.13e-06	4.51e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	5.11e-06	4.5e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.11e-06	4.49e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	5.1e-06	4.49e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	5.09e-06	4.47e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.02e-06	4.42e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—EGFR—chronic obstructive pulmonary disease	4.96e-06	4.36e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—EGFR—chronic obstructive pulmonary disease	4.96e-06	4.36e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.95e-06	4.35e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.95e-06	4.35e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.94e-06	4.35e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.93e-06	4.34e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.85e-06	4.27e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	4.85e-06	4.26e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.84e-06	4.26e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—TGFB1—chronic obstructive pulmonary disease	4.83e-06	4.25e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.8e-06	4.22e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—EGFR—chronic obstructive pulmonary disease	4.74e-06	4.16e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.72e-06	4.15e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.69e-06	4.12e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—TGFB1—chronic obstructive pulmonary disease	4.67e-06	4.11e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—TGFB1—chronic obstructive pulmonary disease	4.67e-06	4.11e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	4.64e-06	4.08e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.62e-06	4.07e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.6e-06	4.04e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—EGFR—chronic obstructive pulmonary disease	4.58e-06	4.03e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—EGFR—chronic obstructive pulmonary disease	4.58e-06	4.03e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.54e-06	3.99e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.51e-06	3.97e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.44e-06	3.9e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.43e-06	3.89e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.39e-06	3.86e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.39e-06	3.86e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.36e-06	3.83e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.35e-06	3.82e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	4.31e-06	3.79e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	4.17e-06	3.67e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	4.17e-06	3.67e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.14e-06	3.64e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.1e-06	3.61e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.07e-06	3.58e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.07e-06	3.57e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.06e-06	3.57e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4e-06	3.52e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.99e-06	3.51e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.99e-06	3.51e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.99e-06	3.5e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.97e-06	3.49e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.97e-06	3.49e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—IL6—chronic obstructive pulmonary disease	3.94e-06	3.47e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.92e-06	3.45e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.91e-06	3.44e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.88e-06	3.41e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	3.87e-06	3.4e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.86e-06	3.4e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—IL6—chronic obstructive pulmonary disease	3.81e-06	3.35e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—IL6—chronic obstructive pulmonary disease	3.81e-06	3.35e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	3.7e-06	3.25e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.68e-06	3.24e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—IL6—chronic obstructive pulmonary disease	3.64e-06	3.2e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.56e-06	3.13e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.56e-06	3.13e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.55e-06	3.12e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.54e-06	3.11e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—IL6—chronic obstructive pulmonary disease	3.52e-06	3.1e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—IL6—chronic obstructive pulmonary disease	3.52e-06	3.1e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.41e-06	3e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.38e-06	2.97e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.35e-06	2.95e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.35e-06	2.94e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.32e-06	2.92e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.29e-06	2.9e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.28e-06	2.89e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.27e-06	2.88e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.27e-06	2.88e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.21e-06	2.82e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.21e-06	2.82e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.12e-06	2.74e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.07e-06	2.7e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.06e-06	2.69e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.01e-06	2.65e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.01e-06	2.64e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.78e-06	2.45e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.69e-06	2.37e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.69e-06	2.37e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.55e-06	2.24e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.47e-06	2.17e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.47e-06	2.17e-05	CbGpPWpGaD
